415 related articles for article (PubMed ID: 33608812)
21. A recent development of new therapeutic agents and novel drug targets for cancer treatment.
Kifle ZD; Tadele M; Alemu E; Gedamu T; Ayele AG
SAGE Open Med; 2021; 9():20503121211067083. PubMed ID: 34992782
[TBL] [Abstract][Full Text] [Related]
22. Adaptive mechanisms of resistance to anti-neoplastic agents.
Ferreira BI; Lie MK; Engelsen AST; Machado S; Link W; Lorens JB
Medchemcomm; 2017 Jan; 8(1):53-66. PubMed ID: 30108690
[TBL] [Abstract][Full Text] [Related]
23. Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung Cancer.
Goff PH; Zeng J; Rengan R; Schaub SK
Semin Radiat Oncol; 2021 Apr; 31(2):133-139. PubMed ID: 33610270
[TBL] [Abstract][Full Text] [Related]
24. Systemic Therapy for Mutation-Driven NSCLC.
Sun L; Marmarelis ME; Langer CJ
Semin Radiat Oncol; 2021 Apr; 31(2):140-148. PubMed ID: 33610271
[TBL] [Abstract][Full Text] [Related]
25. Re-Irradiation of Recurrent Non-Small Cell Lung Cancer.
Hunter B; Crockett C; Faivre-Finn C; Hiley C; Salem A
Semin Radiat Oncol; 2021 Apr; 31(2):124-132. PubMed ID: 33610269
[TBL] [Abstract][Full Text] [Related]
26. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
[TBL] [Abstract][Full Text] [Related]
27. Personal and Prognostic: Tissue and Liquid Biomarkers of Radiotherapeutic Response in Non-Small Cell Lung Cancer.
Jean-Baptiste SR; Feigenberg SJ; Dorsey JF; Kao GD
Semin Radiat Oncol; 2021 Apr; 31(2):149-154. PubMed ID: 33610272
[TBL] [Abstract][Full Text] [Related]
28. A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
Spaggiari L; Bertolaccini L; Facciolo F; Gallina FT; Rea F; Schiavon M; Margaritora S; Congedo MT; Lucchi M; Ceccarelli I; Alloisio M; Bottoni E; Negri G; Carretta A; Cardillo G; Ricciardi S; Ruffini E; Costardi L; Muriana G; Viggiano D; Rusca M; Ventura L; Marulli G; De Palma A; Rosso L; Mendogni P; Crisci R; De Vico A; Maniscalco P; Tamburini N; Puma F; Ceccarelli S; Voltolini L; Bongiolatti S; Morelli A; Londero F
Lung Cancer; 2021 Apr; 154():29-35. PubMed ID: 33610120
[TBL] [Abstract][Full Text] [Related]
29. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
König D; Savic Prince S; Rothschild SI
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671873
[TBL] [Abstract][Full Text] [Related]
30. Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
Attili I; Tarantino P; Passaro A; Stati V; Curigliano G; de Marinis F
Lung Cancer; 2021 Apr; 154():151-160. PubMed ID: 33684660
[TBL] [Abstract][Full Text] [Related]
31. EZH2-mediated epigenetic suppression of SH3BGRL potently inhibits lung cancer progression.
Liu Z; Xu W; Tan X; Li C
Biochem Biophys Res Commun; 2021 Apr; 548():53-59. PubMed ID: 33631674
[TBL] [Abstract][Full Text] [Related]
32. Saikosaponin-d increases radiation-induced apoptosis of hepatoma cells by promoting autophagy via inhibiting mTOR phosphorylation.
Wang B; Min W; Lin S; Song L; Yang P; Ma Q; Guo J
Int J Med Sci; 2021; 18(6):1465-1473. PubMed ID: 33628104
[No Abstract] [Full Text] [Related]
33. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic targeting of cancer stem cells by polyphenols (cancer stem cells targeting).
Ghasemi S; Xu S; Nabavi SM; Amirkhani MA; Sureda A; Tejada S; Lorigooini Z
Phytother Res; 2021 Jul; 35(7):3649-3664. PubMed ID: 33619811
[TBL] [Abstract][Full Text] [Related]
35. Delivery routes matter: Safety and efficacy of intratumoral immunotherapy.
De Lombaerde E; De Wever O; De Geest BG
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188526. PubMed ID: 33617921
[TBL] [Abstract][Full Text] [Related]
36. Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma.
Qin Y; Zheng X; Gao W; Wang B; Wu Y
Mol Ther Oncolytics; 2021 Mar; 20():342-351. PubMed ID: 33614915
[TBL] [Abstract][Full Text] [Related]
37. Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities.
Eddy K; Shah R; Chen S
Front Oncol; 2020; 10():626129. PubMed ID: 33614507
[TBL] [Abstract][Full Text] [Related]
38. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
39. Hypofractionation in Early Stage Non-Small Cell Lung Cancer.
Wrona A; Mornex F
Semin Radiat Oncol; 2021 Apr; 31(2):97-104. PubMed ID: 33610276
[TBL] [Abstract][Full Text] [Related]
40. Fangchinoline exerts anticancer effects on colorectal cancer by inducing autophagy via regulation AMPK/mTOR/ULK1 pathway.
Xiang X; Tian Y; Hu J; Xiong R; Bautista M; Deng L; Yue Q; Li Y; Kuang W; Li J; Liu K; Yu C; Feng G
Biochem Pharmacol; 2021 Apr; 186():114475. PubMed ID: 33609560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
